Semaglutide News and Research

Latest Semaglutide News and Research

Scientists uncover brain circuit that turns cravings into eating behavior

Researchers found that the bed nucleus of the stria terminalis integrates pleasure signals from central amygdala prodynorphin neurons and hunger signals from agouti-related peptide neurons to drive consumption. Manipulating this bed nucleus of the stria terminalis circuit bidirectionally altered food intake and body weight in mice.

11 Sep 2025

Study challenges conventional thinking about the onset of Type 2 diabetes

A study from The University of Texas at San Antonio Health Science Center indicates that changes in the body that lead to Type 2 diabetes occur long before current diagnostic thresholds for prediabetes are met.

11 Sep 2025

Experts warn tiny plastics in arteries may raise heart attack risk

Experts caution that nanoplastics and microplastics may constitute an emerging cardiovascular risk factor, with particles identified in arterial plaques associated with a 4.5-fold increase in major adverse cardiovascular events. Experimental evidence points to inflammation, oxidative stress, and vascular injury as key mechanisms.

10 Sep 2025

Popular weight-loss medications raise pregnancy safety concerns for women

Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers.

8 Sep 2025

WHO expands essential medicines lists with new cancer and diabetes treatments

Today, the World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

5 Sep 2025

Semaglutide may one day be used to treat cocaine addiction

A drug already prescribed for type 2 diabetes and obesity may one day be used to treat cocaine addiction. In animal studies, researchers at the University of Gothenburg, Sweden, found that semaglutide reduced both cocaine use and relapse.

5 Sep 2025

As insurers struggle with GLP-1 drug costs, some seek to wean patients off

After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April.

4 Sep 2025

Weight loss medication semaglutide reduces cocaine seeking behavior in animal study

Scientists have found that the diabetes/weight loss drug Semaglutide, sold commercially under brand names like Ozempic and Wegovy, significantly reduces cocaine-seeking behaviour in rats.

4 Sep 2025

$New hypothesis links internal fat biology to heart failure with preserved ejection fraction$

New hypothesis links internal fat biology to heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person's internal fat tissue, according to the Adipokine Hypothesis, a new way of understanding how fat may impact the heart.

1 Sep 2025

Longitudinal study reveals how GLP-2 analog therapy transforms the intestinal environment

Researchers from Japan discover that glucagon-like peptide-2 (GLP-2) analogs can deeply and beneficially reshape the intestinal environment.

27 Aug 2025

Increasing numbers of bariatric surgery patients turn to GLP-1 drugs

Bariatric surgery is usually effective on its own for weight loss, but an increasing proportion of patients who undergo bariatric surgery start taking one of the new glucagon-like 1 peptide receptor agonist (GLP-1) weight-loss drugs in the years after their surgery, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

27 Aug 2025

GLP-1 receptor agonists improve heart failure outcomes and reduce environmental impact

New research has found that the use of GLP-1 receptor agonists, a class of medications commonly prescribed for patients with obesity and diabetes, reduces the environmental footprint of healthcare and clinical outcomes when used to treat heart failure.

27 Aug 2025

Redefining peptide synthesis with Vapourtec

Vapourtec's Peptide-Builder, a fully automated, high-throughput benchtop peptide synthesizer, has been designed to redefine solid-phase peptide synthesis (SPPS). Compact, efficient and intuitive, it brings a new level of simplicity and performance to peptide synthesis.

27 Aug 2025

Do GLP-1 drugs shrink your muscles? New study explains the risks and what to do

GLP-1 receptor agonists are transforming obesity and diabetes care, but may reduce skeletal muscle mass, raising concerns about sarcopenic obesity. This comprehensive review explores the mechanisms, clinical implications, and mitigation strategies, including exercise, protein intake, and adjunct therapies.

26 Aug 2025